Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin’s lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company was founded in 1999 and is headquartered in Paris, France.
तुलना करने के लिए मीट्रिक्स | CLLS | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधCLLSपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −8.3x | −1.1x | −0.6x | |
PEG अनुपात | −0.13 | 0.05 | 0.00 | |
क़ीमत/बुक | 2.9x | 1.8x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 3.5x | 4.3x | 3.4x | |
अपसाइड (विश्लेषक लक्ष्य) | 96.6% | 24.9% | 41.1% | |
उचित मूल्य अपसाइड | अनलॉक करें | 11.4% | 5.3% | अनलॉक करें |